statut_color,statut,statut_name,NCTId,eudraCT,CTIS,completion_year,clinical_trial_title,acronym,intervention_type
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00121121,,,2005,A Phase Ib Vaccine Trial Evaluating the Safety and Immunogenicity of HIV Lipopeptides by Two Administration Routes (Intramuscular And Intradermal) in Healthy Adult Volunteers. ANRS VAC16 Trial,,BIOLOGICAL
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00120185,,,2006,Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral Na√Øve HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00196586,,,2006,Pilot Study of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin for the Treatment of Chronic Hepatitis C in HIV-HCV Coinfected Patients Non Responders to Three Months of Therapy With Pegylated Interferon Alpha 2a and Ribavirin. ANRS HC09 SECOIIA,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00122603,,,2007,Efficacy and Safety of Regimens Restricted to a Combination of Two Boosted Protease Inhibitors as Potent Antiretroviral Therapy in HIV-1 Infected Patients. ANRS 127 2IP,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00148863,,,2007,Pilot Study on Interferon Gamma in Association With Peg-Interferon Alpha 2a and Ribavirin Among Patients With a Chronic Hepatitis C and Non Responders to the Association of Peg-Interferon Alpha 2b or 2a and Ribavirin ANRS HC16 Gammatri,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00120367,,,2007,Early Intensification of Combination Antiretroviral Therapy Including FUZEON¬Æ in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00117494,,,2007,Randomised Comparative Study of the Efficacy and Safety of Rosuvastatin and Pravastatin in Dyslipidemic Patients Treated With Antiretroviral Agents. Anrs 126,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00118677,,,2007,Long-Term Supervised Treatment Interruption in HIV-Infected Patients Who Started Antiretroviral Treatment With CD4 Over 350/mm3 and Plasma HIV RNA Below 50 000/mL ANRS 116 Trial SALTO,,PROCEDURE
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00121758,,,2007,Randomised Double Blinded Phase II AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptide (LIPO-5) Versus Placebo in Non Infected HIV Volunteers (ANRS VAC 18),,BIOLOGICAL
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00113282,,,2008,Study of the Immunological Efficacy of Adding Subcutaneous Interleukin-2 (IL-2) to an Optimized Antiretroviral Regimen in HIV-1-infected Subjects Experiencing Therapeutic Failure on an Ongoing Antiretroviral Combination With a CD4 Cell Count ‚â§ 200/mm3 ANRS 123 Trial,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00454337,,,2008,Randomized Non-inferiority Study Comparing a Strategy Maintaining Current Enfuvirtide-based Antiretroviral Therapy to a Strategy Replacing Enfuvirtide by an Integrase Inhibitor (Raltegravir) in HIV-1 Infected Subjects With Plasma Hiv-1 RNA Levels Below 400 Copies Per ml.ANRS 138 EASIER,EASIER,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00528060,,,2008,"Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 Cophar 3",ANRS134COPHAR3,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00120757,,,2008,"Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2007-000162-20,,2008,"Essai randomis√© de non-inf√©riorit√© comparant une strat√©gie de maintien du traitement antir√©troviral en cours √† une strat√©gie de substitution de l‚Äôenfuvirtide par un inhibiteur de l‚Äôint√©grase (MK 0518) chez des sujets infect√©s par le VIH-1, ayant un ARN VIH-1 plasmatique inf√©rieur √† 400 copies/ml.",EASIER,DRUG (presumed)
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2007-003203-12,,2008,"Pharmacocin√©tique de l‚Äôatazanavir chez des patients infect√©s par le VIH, trait√©s en premi√®re ligne par l‚Äôassociation atazanavir+ritonavir et emtricitabine+t√©nofovir en prise unique.",COPHAR-3,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00302822,2005-004722-12,,2009,Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00196664,,,2009,"Assessment of the Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin. Multicentric, Double-Blinded, Randomized Study. ANRS HC18 Paropeg",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00122616,,,2009,Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and C Hepatitis Who Failed to Active Treatment for HCV. ANRSHC12 Fibrostop,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00115609,,,2009,Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00490074,,,2009,A Phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost,EV03/ANRSVAC20,BIOLOGICAL
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00460382,,,2009,"Prospective Clinical Trial to Assess Safety and Efficacy of DRV/r(TMC 114/r), ETV(TMC 125) and MK-0518 in Addition to OBT in HIV-1 Infected Patients With Limited to No Treatment Options ANRS 139 TRIO",ANRS139 TRIO,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2007-000670-23,,2009,"Essai pilote √©valuant un traitement antir√©troviral associant le MK-0518, le darunavir/ritonavir (TMC114/r) et l‚Äôetravirine (TMC125) chez les patients infect√©s par le VIH-1, en √©chec virologique et porteurs de virus multi-r√©sistants.",TRIO,DRUG (presumed)
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00574652,2006-004039-31,,2010,"ANRS HC 21 VASCU IL-2, Evaluation of the Cellular Immune Response, Clinical Efficacy and Tolerance After IL-2 Therapy in HCV-related Vasculitis Patients, Resistant to Conventional Therapy.",VASCU-IL2,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01038401,,,2010,Characterization of the Residual Replication of HIV-1 in the Gut-associated Lymphoid Tissue in Patients Receiving Effective Highly Active Antiretroviral Therapy: the ANRS EP 44 Study,EP 44,PROCEDURE
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT00383734,,,2010,"Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE",,DEVICE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00647205,,,2010,Evaluation of 2 Interferon Œ≥ Assays (QuantiFERON TB Gold In-Tube¬Æ and T-SPOT.TB¬Æ) in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT,,DEVICE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01039220,,,2010,Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients,ANRS 2H,BIOLOGICAL
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01008813,,,2010,A Randomized Phase II Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac),,BIOLOGICAL
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00536627,,,2010,"Randomised, Opened, Multicentre Phase I/II Trial in Patients With Chronic Hepatitis B With HBV VL < 12 IU/ml and Under Treatment With NRTI, Which Evaluated Efficacy and Tolerance of Vaccination With Naked DNA on Viral Replication After Analogs' Treatment Interruption. ANRS HB02 VAC-ADN",VAC-ADN,BIOLOGICAL
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2009-016226-13,,2010,Etude de phase II randomis√©e √©valuant l'immunog√©nicit√© et la tol√©rance du vaccin antigrippal A(H1N1)v adjuvant√© comparativement au vaccin antigrippal A(H1N1)v non adjuvant√© chez des patients infect√©s par le VIH (ANRS 151 HIFLUVAC),HIFLUVAC,DRUG (presumed)
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT00657397,,,2011,Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville,Methaville,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2006-005962-38,,2011,"Essai randomis√© de non-inf√©riorit√© comparant la capacit√© √† maintenir le succ√®s virologique d‚Äôune strat√©gie de traitement simplifi√© par une monoth√©rapie d‚Äôinhibiteur de prot√©ase boost√©, le darunavir/r (TMC114/r), par rapport au maintien d‚Äôune trith√©rapie comportant 2 inhibiteurs nucl√©osidiques de la transcriptase inverse (INTI) associ√©s au darunavir/r (TMC114/r) chez des patients infect√©s par le VIH-1 en succ√®s immunovirologique.",MONOI,DRUG (presumed)
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2009-011171-76,,2011,Etude pilote √©valuant l‚Äôint√©r√™t d‚Äôune intensification par maraviroc (Celsentri¬Æ) chez des patients infect√©s par le VIH-1 pr√©sentant une restauration immunitaire insuffisante malgr√© une charge virale contr√¥l√©e par un traitement anti-r√©troviral.,MARIMUNO,DRUG (presumed)
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00421551,,,2011,"A Randomized Multicenter Study With Non-inferiority Hypothesis, Comparing the Availability to Maintain a Complete Viral Suppression by a Monotherapy of Darunavir/r to a NRTI Containing Regimen Including Darunavir/r, in HIV-1 Infected Patients With Previous Prolonged Complete Viral Suppression. ANRS 136 MONOI",,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01164462,,,2011,,DRAG,BIOLOGICAL
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00944541,,,2011,Pilot Study Evaluating Maraviroc (Celsentri¬Æ)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO,145 MARIMUNO,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT00822315,,,2012,"Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00820118,,,2012,"ARNS 141 TIPI : A Pilot Trial to Assess the Ability of an Intermittent Antiretroviral Therapy in Maintaining an Immunological Stability in Antiretroviral na√Øve HIV Infected Adults, With CD4 Count Above 500/mm3",TIPI,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01413152,,,2012,EVALUATION DU RISQUE RESIDUEL DE TRANSMISSION DU VIH CHEZ DES HSH TRAITES AYANT UNE CHARGE VIRALE PLASMATIQUE INDETECTABLE,EP 49 EVARIST,BIOLOGICAL
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT00424814,,,2012,Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. A Multicenter Randomised Phase II/III Open Label Study With a Group of 100 Pregnant Women Receiving Lopinavir/Ritonavir and a Group of 50 Receiving Lopinavir/Ritonavir Plus Zidovudine and Lamivudine. ANRS 135 Primeva,,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00480792,,,2012,"Open-label, Randomized, and Multicentric Phase III Clinical Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV-1-infected Patients With CD4-positive T-lymphocytes Counts Above 200 permm3 ANRS HB 03 VIHVAC-B",VIHVAC-B,BIOLOGICAL
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT00901524,,,2012,"ANRS HC20 Pilot Study, Multicenter, Assessing the Effectiveness of an Optimized Anti HCV (360Œºg/Week Induction of PegIFN-alpha2a + 18mg/kg/j of RBV for 6 Months and Then Depending on the Virological Response to S12, Elongation up S72 to the Dual Anti HCV, With Accompanying Measures) on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV.",ETOC,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2008-000859-10,,2012,"Etude pilote, multicentrique, √©valuant l‚Äôefficacit√© d‚Äôun traitement anti VHC optimis√© (induction par 360¬µg/S de PegIFN-alpha 2a + 18mg/kg/j de RBV pendant 6 mois puis en fonction de la r√©ponse virologique √† S12, allongement jusqu'√† S72 de la bith√©rapie anti VHC, avec mesures d'accompagnement) sur la r√©ponse virologique soutenue chez des patients VHC de g√©notype 1 et 4, non r√©pondeurs et co-infect√©s par le VIH.",ETOC,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00391638,,,2012,Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG.,HB01EMVIPEG,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01065207,,,2012,ANRS HIV CONTROLLERS NATIONAL OBSERVATORY,ANRS CO18,BIOLOGICAL
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2009-015121-37,,2013,Etude multicentrique randomis√©e ouverte comparant la r√©duction virale et la tol√©rance de l‚Äôassociation IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des patients atteints d‚Äôh√©patite chronique C de g√©notype 1,COAT-IFN,DRUG (presumed)
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT01226446,,,2013,Multicenter Open and Prospective Trial Assessing the Efficacy of Vitamin D Supplementation in Addition to Pegylated Interferon Plus Ribavirin in Null-Responders Patients With Chronic Viral Hepatitis C Genotype 1 or 4,ANRS VITAVIC,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT00670839,,,2013,"Open-label, Randomized, and Multicenter Phase III Clinical Trial Comparing Immunogenicity of Double-dose (40 ¬µg at S0, S4 and S24), Versus Standard Dose Vaccination (20 ¬µg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost",B-BOOST,BIOLOGICAL
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01332955,,,2013,Pilot Study of PegInterferon-Ribavirin-Telaprevir Efficacy and Tolerability in HIV-HCV Coinfected Patients Who Had Previously Failed a PegInterferon-Ribavirin Regimen. (ANRS HC26 TelapreVIH),TelapreVIH,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT01066962,2009-015113-44,,2013,An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral na√Øve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001),ANRS 143,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT01033760,,,2013,Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM),,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00323804,2005-002937-11,,2013,"Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients.",,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00116454,,,2013,A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis,Lipiocis,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01022476,,,2013,"A Pilot Study of Pharmacokinetics, Tolerance and Efficacy of Raltegravir Combined to Two Fully Active Molecules Among Nucleosi(ti)de Analogs and Enfuvirtide Before and After Liver Transplant in HIV Infected Patients With End Stage Liver Disease (ANRS 148 LIVERAL)",LIVERAL,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2009-014616-36,,2013,"Etude pilote de la pharmacocin√©tique, de la tol√©rance et de l‚Äôefficacit√© du ralt√©gravir associ√© √† deux mol√©cules actives parmi les analogues nucl√©osi(ti)diques et l‚Äôenfuvirtide, avant et apr√®s transplantation h√©patique chez des patients VIH+ en insuffisance h√©patique s√©v√®re.",LIVERAL,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00265642,,,2013,Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C,Fibrosar,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00946595,,,2014,A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL,ANRS 140 DREAM,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01207986,,,2014,Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study,EP48 HIV CHEST,RADIATION
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01725542,2012-002589-11,,2014,"Pilot Study to Assess the Efficacy and Tolerance to a QUadruple Therapy With Asunaprevir , Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a, in HIV-HCV Genotype 1 or 4 Coinfected Patients Previously Null Responders to a Standard Pegylated Interferon -Ribavirin Regimen",QUADRIH,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT00918307,,,2014,Comparison of the Efficacy and Safety of Varenicline Versus Placebo for Smoking Cessation Among HIV-infected Patients. A Randomized Double Blind Controlled Trial,Inter-ACTIV,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT01335529,,,2014,"Pilot Study to Assess the Efficacy and Safety of Boceprevir, in Combination With Peg-Interferon Alfa and Ribavirin, in Patients With HCV/HIV Co-infection Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin",BocepreVIH,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01463956,,,2015,Pilot Study on the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT),,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT02125500,2013-002607-33,,2015,Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01952587,,,2015,Frequency and Functional Impact of the c.32A>T Genetic Polymorphism of TLR7 in Women Infected With HIV-1 : the ANRS EP53 Study,X LIBRIS,BIOLOGICAL
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01127204,,,2015,"Randomized Phase 3 Trial to Evaluate Two Simplified Antiretroviral Treatment Strategies in HIV Infected Children, Treated by Antiretroviral Triple Therapy Before One Year of Age, in Virological Success in Africa (Burkina Faso, C√¥te d'Ivoire, Rwanda)",,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02107365,,,2015,"Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen",,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01453192,,,2015,"National, Multicenter, Phase III Prospective Trial About Clinical and Immunological Follow-up After Renal Transplantation in HIV-1 Infected Patients With End Stage Chronic Renal Insufficiency",ANRS153TREVE,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT01605890,,,2015,"ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients",VIH-2,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02038842,,,2016,Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU¬Æ-MultiHIV B / LIPO-5; GTU¬Æ-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection,VRI01,BIOLOGICAL
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT02157311,2014-000146-29,,2016,"Evaluation of the Capacity of a Weekly Strategy of 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV-1 Infected Patients With Undetectable Viral Load for at Least 12 Months, to Maintain a Virological Success With This Intermittent Maintenance Therapy After a Successful Continuous Induction Therapy.",ANRS162-4D,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02093754,,,2016,Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients: a European Multicentre Study,ANRS ECHAM,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01899196,,,2016,EPICARDIAL ADIPOSE TISSUE AND CORONARY RISK IN HIV-INFECTED PATIENTS,ANRS EP 52,BIOLOGICAL
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01473472,,,2016,On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men,IPERGAY,DRUG
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT02384967,,,2016,"Phase II Trial Assessing the Efficacy of a Reduced Dose Strategy of Darunavir to 400 mg/d in HIV-1 Infected Patients Virologically Suppressed Under a Once Daily Regimen Including Darunavir 800 mg/d and Two Nucleoside Reverse Transcriptase Inhibitors (NRTI), to Maintain the Viral Load Lower Than 50 Copies / mL at 48 Weeks of Treatment",DARULIGHT,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT01348308,,,2016,"Optimized Phase III Trial of Immuno-stimulation With Maraviroc, a CCR5 (Chemokine Receptor 5) Antagonist, Combined With Anti Retroviral Therapy in Advanced, Late Diagnosed HIV-1 Infected Patients With an AIDS-defining Event and/or CD4 (Cluster of Differentiation 4) Counts Below 200 Cells/mm¬≥. ANRS 146 OPTIMAL",OPTIMAL,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT02099474,2013-004571-12,,2017,Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy,ANRS 160 RalFE,OTHER
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,NCT01492985,,,2017,Evaluation of a Therapeutic Immunization Strategy Associating a DNA Vaccine (GTU-MultiHIV B) Followed by a Lipopeptide Vaccine (LIPO-5) in the Control of Viral Replication Following Antiretroviral Treatment Interruption in HIV-1 Infected Patients With a CD4 Cell Count ‚â• 600/mm3,,BIOLOGICAL
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT02592174,,,2017,"Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study",HAND55-70,OTHER
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02527096,2015-001492-44,,2017,A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir¬Æ) and Dolutegravir(Tivicay¬Æ) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol,,DRUG
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT01426243,,,2017,The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient,EP46 NOVAA,BIOLOGICAL
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT02273765,,,2018,"Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-na√Øve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis",REFLATE TB2,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01895920,,,2018,,TRANSBioHIV,OTHER
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01269632,,,2018,Long Term Evaluation of Young Adults Born to HIV-infected Mothers. A Cohort of Young Adults Infected With HIV Since Birth or During Childhood,CO19 COVERTE,BIOLOGICAL
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT02212379,,,2018,Dual Therapy Combining Raltegravir With Etravirine Maintains a High Level of Viral Suppression Over 96 Weeks in Long-term Experienced HIV-infected Individuals Over 45 Years on a PI-based Regimen: Results From the Phase II ANRS 163 ETRAL Study,,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT01942655,,,2018,ANRS RF002 Intestipax : Interleukin-23 (IL-23)/Interleukin-12 (IL-12) Imbalance and T Lymphocyte Polarization in HIV Infection,INTESTIPAX,OTHER
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02987530,2016-001683-11,,2020,"Phase III Multicenter Randomized Trial Evaluating in Patients At the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/emtricitabine and Dolutegravir or Tenofovir/emtricitabine and Darunavir/cobicistat",OPTIPRIM-2,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02738502,,,2020,An Open-label Phase II Pilot Study of Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors,MONOGEST,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02906137,,,2020,Altered Homing of T Lymphocytes to the Gut and Poor Immune Reconstitution of the Intestinal Mucosa in Treated HIV-infected Individuals,GALT,OTHER
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT04008927,,,2021,Towards Ending HCV Infection Among Active Drug Users: a Community-based Intervention in Montpellier.,ICONE,DIAGNOSTIC_TEST
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT02626286,,,2021,Prevention of HIV Infection in Men Who Have Sex With Men in Sub-Saharan Africa: Feasibility and Interest of a Quarterly Preventive Global Care (CohMSM),CohMSM,OTHER
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT03671291,,,2021,National Survey on Missed Opportunities to Pre-exposure Prophylaxis for Prevention of Human Immunodeficiency Virus-infection.,,BEHAVIORAL
üü©,1,1 : r√©sultats post√©s ou publi√©s dans les 12 mois,NCT03459157,,,2021,Access to Pre-exposure Prophylaxis for Men Who Have Sex With Men: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP),CohMSM-PrEP,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT03870438,,,2022,Prevention of Mother-to-child Transmission of HIV-1: Programme Evaluation and Innovative Responsive Intervention Integrated in the Expanded Programme of Immunization. PROMISE-EPI Study,PROMISE-EPI,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT02287961,,,2022,Natural History of Anal Human Papillomavirus Infection and Associated Disease in HIV-infected Men Who Have Sex With Men: Towards an Evidence Base for the Prevention of Anal Cancer.,APACHES,PROCEDURE
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT05311865,,,2022,Transmission of Covid-19 During Clubbing Events in Closed Places,ITOC,OTHER
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT04824638,,,2023,A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of Vaccine,CoviCompareP,BIOLOGICAL
üüß,2,2 : r√©sultats post√©s ou publi√©s entre 12 et 36 mois,NCT04120415,2019-002818-40,,2023,"EHVA T02 (European HIV Vaccine Alliance Therapeutic Trial 02)/ANRS VRI07: A Phase II Randomised, Placebo-controlled Trial of Vedolizumab With or Without Therapeutic HIV MVA Vaccine in Individuals Who Started Antiretrovirals During Primary or Chronic Infection",,BIOLOGICAL
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT04133012,,,2023,A Prospective Study Aiming to Determine the Cartography of Virological Reservoir Related to Antiretroviral Concentrations in Chronic HIV-1 Patients Treated with a First Line of Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors (NRTIs).,DOLUVOIR,OTHER
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT04842682,,,2024,A Phase I Multicenter Double-blind Placebo Controlled Dose Escalation Trial of an Adjuvanted Anti-CD40 mAb Fused to Env GP140 HIV Clade C ZM-96 (CD40.HIVRI.Env) Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Participants,,BIOLOGICAL
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT05385588,,,2024,"Aging With HIV and Neurocognitive Decline, a Follow-up Study",AgingHAND,OTHER
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT04597424,,,2024,Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP),DOXYVAC,DRUG
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2020-005888-31,,,"A phase I, prophylactic HIV vaccine trial to evaluate the safety and immunogenicity of HIV Clade C DREP alone and in Combination with a Clade C ENV protein in healthy HIV-uninfected adults.",EHVA_P01/ANRS_VRI08,DRUG (presumed)
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2019-001961-34,,,"ANRS 173 ALTAR A randomized, open-label, phase III trial comparing a dual nucleoside analogues strategy preceded by an induction period with an integrase inhibitor based triple therapy to an immediate two-drug strategy with dolutegravir plus lamivudine in ART na√Øve people living with HIV with viral load < 50 000 cp/mL and CD4 cells >300/mm3 
 
 
 ANRS 173 ALTAR Essai randomis√© de phase III, ouvert, comparant une strat√©gie de bith√©rapie d‚Äôanalogues nucl√©osidiques pr√©c√©d√©e d‚Äôune phase d‚Äôinduction avec une trith√©rapie √† base d'inhibiteur d‚Äôint√©grase √† une strat√©gie de bith√©rapie imm√©diate comportant dolutegravir plus lamivudine chez des personnes vivant avec le VIH, na√Øves de traitement antir√©troviral, ayant une charge virale < √† 50 000 copies/mL et des lymphocytes CD4 > 300/mm3",ALTAR,DRUG (presumed)
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2006-003940-50,,,ESSAI RANDOMISE MULTICENTRIQUE DE PHASE III COMPARANT L‚ÄôIMMUNOGENICITE ET LA TOLERANCE DE TROIS SCHEMAS DE VACCINATION CONTRE LE VIRUS DE L‚ÄôHEPATITE B CHEZ DES PATIENTS INFECTES PAR LE VIH AYANT DES LYMPHOCYTES T CD4 SUPERIEURS A 200/mm3,VIHVAC-B,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2019-002829-29,,,"Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP) 
 
 
 Pr√©vention combin√©e des infections sexuellement transmissibles (IST) chez les hommes ayant des rapports sexuels avec des hommes utilisant le TDF/FTC par voie orale pour la prophylaxie pr√©exposition au VIH (PrEP)",Doxyvac,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2021-000509-26,,,"A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS CoV-2 infection administered with two doses of vaccine (D1-D29) and in adult volunteers with documented history of SARS CoV-2 infection (of more than 6 months) administered with only one dose of vaccine 
 
 
 Essai de phase II √©valuant l'immunog√©nicit√© et la s√©curit√© du vaccin √† ARNm COVID-19 BNT162b2 chez des participants adultes sans ant√©c√©dents d'infection par le SARS CoV-2, administr√©s avec deux doses de vaccin (J1-J29) et chez des participants adultes ayant des ant√©c√©dents document√©s d'infection par le SRAS CoV-2 (de plus de 6 mois), administr√©s avec une seule dose de vaccin.",NA,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2017-000040-17,,,"Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral treatment taken 4 consecutive days per week versus continuous therapy 7/7 days per week in HIV-1 infected patients with controlled viral load under antiretroviral therapy 
 
 
 Essai multicentrique, en ouvert, randomis√© en 2 groupes parall√®les, √©valuant la non-inf√©riorit√© d‚Äôun traitement de maintenance √† 4 jours cons√©cutifs sur 7 versus la poursuite du traitement antir√©troviral en continu, chez des patients en succ√®s th√©rapeutique sous ARV.","QUATUOR 
 
 
 QUATUOR",DRUG (presumed)
